Clinical Evaluation of the Combination of Symptoms and Symptoms With General Treatment for Acute Hemorrhagic Stroke

Clinical Evaluation and Study on the Combination of Disease and Syndrome With General Treatment for Acute Hemorrhagic Stroke

NCT04946474•Peking University Third Hospital

View on ClinicalTrials.gov

Summary

Objective To evaluate whether Xingnaojing injection combined with Naoxueshu oral liquid can significantly improve the clinical outcome of patients with intracerebral hemorrhage. Secondary objectives included to evaluate whether combined application of Xingnaojing injection and Naoxueshu oral liquid can promote hematoma absorption or reduce perihematoma cerebral edema in patients with intracerebral hemorrhage

Detailed Description

Eligibility

Age

18 - 80 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•① It meets the diagnostic criteria of primary cerebral hemorrhage.
•* Within 72 hours of onset.
•* National Institutes of Health Stroke Scale (NIHSS) score ≥4 points.
•④ Glasgow Coma Scale (GCS) score \> Eight points.
•⑤ Age 18-80. Patient or legal representative informed consent, and sign informed consent.

Exclusion Criteria

•(1) known to Xingnaojing, cerebral hemorrhage or related drug ingredients allergic.
•* The patients with previous stroke history and remaining sequelae affected the outcome assessment, that is, the modified Ranking scale (MRS) score before the onset of stroke was ≥2 points.
•(3) known by amyloid cerebrovascular disease, vascular malformation, aneurysm, blood coagulation dysfunction, anticoagulation and antiplatelet drug treatment, thrombolysis therapy, bleeding after infarction after conversion, haematology, moyamoya disease, primary or metastatic tumor, venous sinus thrombosis, and vascular inflammation caused by clear etiology of patients with cerebral hemorrhage or primary intraventricular hemorrhage.
•(Note: "After anticoagulant or antiplatelet therapy" refers to patients with intracerebral hemorrhage following anticoagulant and antiplatelet therapy, and these patients were excluded from this study.) (4) Patients with traumatic cerebral hemorrhage. (5) patients with active gastrointestinal ulcer or other definite tendency of rebleeding.

Locations (1)

Peking Yniversity Third Hospital

Beijing, China

Key Dates

Start Date

June 1, 2019

Primary Completion Date

July 1, 2020

Completion Date

September 1, 2021

Last Updated

June 30, 2021

Enrollment

520

ESTIMATED participants

Conditions

Acute Hemorrhagic Stroke

Interventions

Xingnaojing injection + Shuxuetong oral liquid

DRUG

AI-Driven Early Warning System for Perioperative Risks in Acute Hemorrhagic Stroke

NCT06998082

Acute Hemorrhagic Stroke

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 30, 2021Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions